Effect of Venetoclax Combined with CLAG-MI Regimen on Acute Myeloid Leukemia in Children and Its Influence on Flow MRD
Objective To investigate the efficacy of venetoclax combined with cladribine+high-dose cytarabine+mitox-antrone+G-CSF(CLAG-MI)regimen in the treatment of childhood acute myeloid leukemia(AML)and its effect on flow minimal residual disease(MRD).Methods 64 children with acute myeloid leukemia were randomly divided into experimental group(n = 32)and control group(n =32).The control group was treated with CLAG-MI and the experimental group was treated with Vene-toclax.The clinical efficacy was compared between the 2 groups;the blood routine indicators,immune function and flow MRD ex-pression before and after treatment were compared between the two groups;the incidence rate of adverse reactions was compared between the two groups.Results Compared with the total effective rate of the control group(50.00%,16/32),the total effective rate of the experimental group(75.00%,24/32)was significantly higher(P＜0.05).After treatment,the platelet count and red blood cell count were significantly increased,and the proportion of bone marrow blasts,CD3+and CD4+levels were significantly decreased in the two groups.Compared with the control group,the platelet count and red blood cell count were significantly in-creased,and the proportion of bone marrow blasts,CD3+and CD4+levels were significantly lower in the experimental group(P＜0.05).Compared with those before treatment,the positive rate of MRD expression was significantly decreased in both groups,and the difference was statistically significant(P＜0.05).The incidence rate of adverse reactions in the control group[21.87(7/32)]was not significantly different from that in the experimental group[9.37%(3/32)](P＞0.05).Conclusion VEN com-bined with CLAG-MI regimen in the treatment of children with acute myeloid leukemia can effectively improve the clinical efficacy and promote flow MRD conversion,with high safety.
万方数据
维普
